Evidence map›Paper›PMID 38985541›Full record

ArticleThe Journal of antimicrobial chemotherapy2024

The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.

Marie Wijk, Kamunkhwala Gausi, Samantha Malatesta, Sarah E Weber, Richard Court, Bronwyn Myers, Tara Carney, Charles D H Parry, C Robert Horsburgh, Laura F White and 7 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marie WijkDepartment of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-6013-8210
Kamunkhwala GausiDepartment of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-9002-8087
Samantha MalatestaDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Sarah E WeberSection of Infectious Diseases, Boston University School of Medicine and Boston Medical Centre, Boston, MA, USA.
Richard CourtDepartment of Medicine, University of Cape Town, Cape Town, South Africa.
Bronwyn MyersCurtin enAble Institute, Curtin University, WA, Australia.
Tara CarneyMental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.
Charles D H ParryMental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.
C Robert HorsburghDepartment of Epidemiology, Boston University School of Public Health, Boston, MA, USA.ORCID 0000-0001-6838-7895
Laura F WhiteDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Lubbe WiesnerDepartment of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-9070-8699
Robin M WarrenDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Caitlin UrenDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-2358-0135
Helen McIlleronDepartment of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0982-6226
Frank KloproggeInstitute for Global Health, University College London, London, UK.ORCID 0000-0001-7213-4559
Paolo DentiDepartment of Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-7494-079X
Karen R JacobsonSection of Infectious Diseases, Boston University School of Medicine and Boston Medical Centre, Boston, MA, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Investigating bacterial contributions to TB treatment response: a focus on in-host pathogen dynamicsR01AI155765 · NIAID · HARVARD MEDICAL SCHOOL · PI FARHAT, MAHA · 2020 to 2024
$3.7M
The impact of alcohol consumption on TB treatment outcomesR01AI119037 · NIAID · BOSTON MEDICAL CENTER · PI JACOBSON, KAREN R · 2016 to 2020
$3.3M
Adult Clinical Trial GroupNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS R01 AI119037NIAID NIH HHS R01 AI155765NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIH HHS UM1 AI068634United States National Institute of Allergy and Infectious Diseases R01AI119037Wellcome TrustWellcome Trust Sir Henry Dale Fellowship 220587/Z/20/Z
6 · The paper itself

Abstract

backgroundIn South Africa, an estimated 11% of the population have high alcohol use, a major risk factor for TB. Alcohol and other substance use are also associated with poor treatment response, with a potential mechanism being altered TB drug pharmacokinetics.

objectivesTo investigate the impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs in participants with pulmonary TB.

methodsWe prospectively enrolled participants ≥15 years old, without HIV, and initiating drug-susceptible TB treatment in Worcester, South Africa. Alcohol use was measured via self-report and blood biomarkers. Other illicit substances were captured through a urine drug test. Plasma samples were drawn 1 month into treatment pre-dose, and 1.5, 3, 5 and 8 h post-dose. Non-linear mixed-effects modelling was used to describe the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol. Alcohol and drug use were tested as covariates.

resultsThe study included 104 participants, of whom 70% were male, with a median age of 37 years (IQR 27-48). Alcohol use was high, with 42% and 28% of participants having moderate and high alcohol use, respectively. Rifampicin and isoniazid had slightly lower pharmacokinetics compared with previous reports, whereas pyrazinamide and ethambutol were consistent. No significant alcohol use effect was detected, other than 13% higher ethambutol clearance in participants with high alcohol use. Methaqualone use reduced rifampicin bioavailability by 19%.

conclusionNo clinically relevant effect of alcohol use was observed on the pharmacokinetics of first-line TB drugs, suggesting that poor treatment outcome is unlikely due to pharmacokinetic alterations. That methaqualone reduced rifampicin means dose adjustment may be beneficial.

Indexed as

Antitubercular AgentsRifampinAdultAlcohol DrinkingEthambutolFemaleHumansIsoniazidMaleMiddle AgedProspective StudiesPyrazinamideSouth AfricaSubstance-Related DisordersTuberculosis, PulmonaryYoung AdultAntitubercular AgentsEthambutolIsoniazidPyrazinamideRifampin

Identifiers

PMID38985541
PMCPMC11290884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.